EX-99.1 2 dp18989_ex9901.htm EXHIBIT 99.1
Exhibit 99.01
 
Press Release
www.shire.com
  
 
 
August 26, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company
 
Notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification
State
Yes/No
An acquisition or disposal of voting rights
YES
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
 
NO
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
NO
An event changing the breakdown of voting rights
NO
Other (please specify):
NO

3. Full name of person(s) subject to the notification obligation:
EXCELLERATE HRO
SPS (GSY) LTD
 
4. Full name of shareholder(s) (if different from 3.):
N/A
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
31/5/2010
6. Date on which issuer notified:
25/8/2010
7. Threshold(s) that is/are crossed or reached:
BELOW 3%
8. Notified details:
  

A: Voting rights attached to shares

 
Class/type of
shares
 if possible
using the ISIN
CODE
Situation previous to
the Triggering
transaction
Resulting situation after the triggering
transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of
shares
Number of voting
rights
% of voting
rights
     
Direct
Direct
Indirect
Direct
Indirect
ORD 5p Shs & ADRs 3:1
JE00B2QKY057
 
 
  
 
N/A
    
BELOW
3%
  

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of
financial
instrument
Expiration
date
Exercise/Conversion
Period/ Date
Number of voting
rights that may be
acquired if  the instrument
is exercised/converted
% of voting
rights
N/A
        
 
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
 
Resulting situation after the triggering transaction
 
Type of financial
instrument
Exercise
price
Expiration
date
Exercise/
Conversion
period
Number of voting
rights instrument
refers to
% of voting rights
 
N/A
 
 
 
 
Nominal
Delta
 
 
 


Total (A+B+C)
  
Number of voting rights
Percentage of voting rights
   

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 

Proxy Voting:
 
10. Name of the proxy holder:
 
 
N/A
11. Number of voting rights proxy holder will cease to hold:
N/A
12. Date on which proxy holder will cease to hold voting rights:
N/A

13. Additional information:
  
14. Contact name:
LIAN MCLAUGHLIN
15. Contact telephone number:
01481 726088

Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, 01256 894746
 
For further information please contact:

Investor Relations
    
     
Eric Rojas
erojas@shire.com
+1 781 482 0999

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com